Cargando…
Hemoadsorption in critically ill patients with or without COVID-19: A word of caution
Autores principales: | Putzu, Alessandro, Schorer, Raoul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196317/ https://www.ncbi.nlm.nih.gov/pubmed/34148009 http://dx.doi.org/10.1016/j.jcrc.2021.06.007 |
Ejemplares similares
-
Reply: Does adjunctive hemoadsorption with CytoSorb® affect survival of COVID-19 patients on ECMO? A critical statement
por: Putzu, Alessandro, et al.
Publicado: (2021) -
Mortality and adverse events of hemoadsorption with CytoSorb® in critically ill patients: A systematic review and meta‐analysis of randomized controlled trials
por: Heymann, Marc, et al.
Publicado: (2022) -
The Effect of CytoSorb on Inflammatory Markers in Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials*
por: Heymann, Marc, et al.
Publicado: (2023) -
Effect of extracorporeal hemoadsorption in critically ill patients with COVID-19: A narrative review
por: Chang, Kaixi, et al.
Publicado: (2023) -
Hemoadsorption therapy in the critically ill: solid base but clinical haze
por: Honoré, Patrick M., et al.
Publicado: (2019)